CollPlant Biotechnologies (NASDAQ:CLGN) Releases Earnings Results, Misses Estimates By $0.71 EPS

CollPlant Biotechnologies (NASDAQ:CLGN) posted its earnings results on Thursday. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.71), FiscalAI reports. The business had revenue of $0.06 million during the quarter, compared to analysts’ expectations of $6.78 million. CollPlant Biotechnologies had a negative net margin of 491.31% and a negative return on equity of 102.00%.

CollPlant Biotechnologies Stock Performance

NASDAQ CLGN traded down $0.12 on Thursday, hitting $0.63. 35,034 shares of the stock were exchanged, compared to its average volume of 78,633. CollPlant Biotechnologies has a 52-week low of $0.50 and a 52-week high of $4.98. The firm has a market capitalization of $8.10 million, a P/E ratio of -0.62 and a beta of 3.02. The stock has a fifty day moving average price of $0.96 and a two-hundred day moving average price of $1.70.

Analysts Set New Price Targets

A number of equities analysts have commented on CLGN shares. D. Boral Capital cut shares of CollPlant Biotechnologies from a “buy” rating to a “hold” rating in a research note on Friday, February 6th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of CollPlant Biotechnologies in a report on Wednesday, January 21st. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $11.50.

About CollPlant Biotechnologies

CollPlant Biotechnologies Ltd. (NASDAQ: CLGN) is a regenerative medicine company that develops and commercializes recombinant human collagen (rhCollagen) and 3D bioprinting technologies for medical and aesthetic applications. The company’s proprietary plant-based rhCollagen is produced using genetically engineered tobacco plants to provide a scalable, animal-free source of human collagen that meets regulatory standards.

CollPlant’s product portfolio includes Vergenix™ wound care matrices and dermal fillers for aesthetic and reconstructive purposes, as well as a range of bioinks designed for 3D bioprinting of soft and hard tissues.